IFNA1 and systemic lupus erythematosus: This finding offers a rational explanation for why blocking the IFN-I receptor showed efficacy only in a subset of patients with SLE with a high IFN signature18 and highlights that anti-IFN-I therapies are more likely to be effective in patients with high levels of IFN-I rather than a high IFN signature.